Aclaris Therapeutics Stock News

Aclaris Therapeutics on Monday said it would stop development of its rheumatoid arthritis treatment after it failed in a mid-stage trial.

Aclaris Therapeutics is a developer of kinome-based medicines for immune-inflammatory and oncology indications. The company's platform, KINect, helps advance small molecules targeting kinases to repli

WAYNE, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory

An analyst raised his price target on the biotech. He also maintained his buy recommendation on the stock.

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.31 per share a year ago.

Aclaris Therapeutics, Inc. results from a phase 2b study using zunsemetinib for the treatment of patients with rheumatoid arthritis are expected to be released by Q4 of 2023. The global rheumatoid art

Low-priced stocks tend to be more trouble than they are worth. On the rare occasion, however, these equities can turn out to be diamonds in the rough.

The biotech has completed enrollment in the next phase of an important development program. It is aiming to get a rheumatoid arthritis drug to market.

WAYNE, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.31 per share a year ago.

WAYNE, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory d

In a high-interest-rate environment, cash is king. All biotech companies will need to continue spending to finance their R&D.

WAYNE, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory

Markets were mixed, with large caps rising as small caps gave up ground. BridgeBio Pharma showed positive trial results for a treatment for a disease that limits growth.

Aclaris' phase 2a clinical study of zunsemetinib in treating a chronic skin condition didn't meet its primary or secondary endpoints. The company continues to move forward with other clinical studies